Molecular Analysis and Treatment Options of Thymic Malignancies

Recruiting

• Conditions: Thymic Epithelial Tumor; Thymic Carcinoma; Thymic Cancer

• Registration Number: NCT05667948
• Lead Sponsor: Shanghai Chest Hospital

Brief Summary

Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies.

In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-01-01
• Study First Submitted: 2022-11-30
• Study First Submitted QC: 2022-12-28
• Study First Posted: 2022-12-29
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-20
• Last Update Posted: 2025-05-22
• Primary Completion: 2025-12-31
• Study Completion: 2026-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Histologically proven diagnosis of thymic malignancies
• 18 years of age or older
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease control rate (DCR)	20 years	Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
Progression-free survival (PFS)	20 years	Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
Objective response rate (ORR)	20 years	Collect detailed clinical information on patients with thymic malignancies via the electronic medical records

Secondary Outcome Measures

Name	Time	Method
Overall survival (OS)	20 years	Collect detailed clinical information on patients with thymic malignancies via the electronic medical records

Trial Locations

Locations (1)

Xiaomin Niu; 🇨🇳 Shanghai, Shanghai, China